EVALUATION OF BIOMARKERS PREDICTIVE OF BENEFIT FROM THE PD-1 INHIBITOR MK-3475 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND BRAIN METASTASES

Yale Univ

Investigators